Most recurrent urinary tract infections are caused by the reintroduction of bacteria, usually Escherichia coli, from the fecal reservoir (8). Whereas more than 160 serogroups of E. coli are known, 13 most frequently are isolated as etiological agents of these infections (12). Knowledge of serogroup is required for epidemiological reasons and to help differentiate between new and reemerged strains. Bacterial agglutination is the conventional method for serogrouping E. coli. However, specificity frequently is masked because immunoglobulin M (IgM) in purchased antisera characteristically reveals cross-reacting or shared antigenic factors.
Thirteen serogroups of Escherichia coli most frequently are responsible for urinary tract infections in humans. Knowledge of serogroup is required for epidemiological reasons and to help differentiate between new and reemergent strains in infected patients. Coagglutination and bacterial agglutination were compared as serodiagnostic tools for identifying groups of E. coli associated with these infections. In contradistinction to bacterial agglutination, coagglutination showed no cross-reactions for 12 of the 13 known strains obtained from the Center for Disease Control. A single antiserum, E. coli 04, caused bacterial agglutination and not coagglutination. In addition, staphylococcal cells that were coated with antiserum reacted with sheep erythrocytes that had been treated with soluble extract of E. coli. The latter reaction, cohemagglutination, was as specific and rapid as coagglutination; easily visible patterns of clumping developed within 1 min after sensitized staphylococci and E. coli reagent were mixed. These results revealed a method that is sensitive and reproducible for identifying serogroups of E. coli responsible for urinary tract infections.
Most recurrent urinary tract infections are caused by the reintroduction of bacteria, usually Escherichia coli, from the fecal reservoir (8) . Whereas more than 160 serogroups of E. coli are known, 13 most frequently are isolated as etiological agents of these infections (12) . Knowledge of serogroup is required for epidemiological reasons and to help differentiate between new and reemerged strains. Bacterial agglutination is the conventional method for serogrouping E. coli. However, specificity frequently is masked because immunoglobulin M (IgM) in purchased antisera characteristically reveals cross-reacting or shared antigenic factors.
Coagglutination, a simple and rapid serological procedure described by Kronvall in 1973 for typing pneumococci (10) , has provided new dimensions to diagnostic microbiology. In principle, the Cowan I strain of Staphylococcus aureus, rich in protein A on its outer surface, nonspecifically binds the Fc portion of IgG in immune serum. A well-defined pattern of clumping follows the addition of antigen specific for the free Fab portion. This procedure may be used to identify streptococci (2), gonococci (3), salmonellae (5), shigellae (5), mycobacteria (9), Haemophilus influenzae type b (13) , and meningococci (14).
The present study was designed to assess coagglutination as a diagnostic tool for identifying those E. coli serogroups associated with uri-41 nary tract infections; the method proved more specific and expeditious than bacterial agglutination. In addition, the staphylococcal cells prepared for coagglutination detected soluble E. coli group-specific antigen adsorbed to sheep erythrocytes (SRBC). Table 1 . Seventy-six isolates of E. coli were selected from urine specimens routinely submitted to the Microbiology Section, Veterans Administration Medical Center for identification to species and serogrouping of microbial populations of -105/ml.
The Cowan I strain of S. aureus (ATCC 12598) was purchased from the American Type Culture Collection, Rockville, Md. S. aureus deficient in protein A (Wood 46) was provided by Goran Kronvall, University of Lund, Lund, Sweden.
All strains were maintained on blood agar base (Difco, Detroit, Mich.) until tested.
Antisera. E. coli antisera were obtained from CDC (Table 1) .
Bacterial agglutination. The procedure employed was recommended in the package insert of CDC antisera for tube agglutination. The highest dilution of antiserum yielding 2++ agglutination with Coagglutination test. One drop of E. coli suspension was placed on a slide, and an equal volume of coated or control staphylococcal suspension was added. The mixture was stirred thoroughly with a wooden applicator stick. After 2 min at 22°C, the slide was examined against a dark background for agglutination. Reactions were graded as negative, when the mixture remained in a uniform suspension, or + to ++++, based on the degree of agglutination and size of aggregates formed; + was a finely granular, uniform agglutination, whereas ++++ was agglutination of all microorganisms and a clear supernatant fluid. A reaction of ++ or greater was considered positive.
Cohemagglutination test. E. coli suspensions were prepared as previously described, except that optical densities were standardized between 0.60 and 0.70 at 640 nm. The suspensions were centrifuged for 15 min at 2,500 x g; 4.25 ml of the decanted supernatant fluid was mixed with 0.5 ml of 95% ethanol to yield a final ethanol concentration of 10%. One volume of the packed pellet of SRBC washed in PBS was suspended in 30 volumes of the E. coli supernatant fluid-ethanol mixture. The combination was incubated for 1 h in a water bath at 37°C and then centrifuged at 25,000 x g; the sedimented SRBC were washed in PBS and resuspended to a final concentration of 10% in PBS. One drop of these treated, washed, and reconstituted SRBC was mixed on a slide with 1 drop of sensitized or control staphylococcal suspension. The combination was stirred thoroughly with a wooden applicator stick. After 2 min over indirect light, the slides were examined for hemagglutination. Reactions were graded from negative to ++++ according to degree of hemagglutination. Antigen-coated SRBC were tested for cross-reactivity with each of the staphylococcal preparations sensitized with heterologous antibody.
RESULTS
The biochemical profiles of the known serotypes of E. coli strains (CDC) are shown in Table 1 . Of the seven profiles recorded, two (5144552 and 5144572) represented eight of the 13 strains. The comparative serological specificities of group-specific antisera against these strains, as determined by bacterial agglutination, coagglutination, and cohemagglutination, are presented in Table 2 . In bacterial agglutination, VOL. 11, 1980 latter study. The remaining 27 isolates failed to react with any of the 13 antisera. Not shown in Table 3 is the observation that, among the 49 isolates tested, 17 different biochemical profiles were obtained. The control indicators, Cowan I strain treated with PBS and Wood 46 strain treated with E. coli antiserum, did not react with any of the E. coli suspensions. Also, as expected, SRBC treated with PBS instead of E. coli extract did not agglutinate with any of the staphylococcal preparations coated by CDC antisera. There was no evidence of autoagglutination in saline or PBS employed as controls for either bacterial agglutination, coagglutination, or cohemagglutination.
COAGGLUTINATION OF E. COLI 43 DISCUSSION The API 20E numerical profile is an acceptable guide for identifying enterobacteria. However, although a spectrum of numbers is employed reliably to label a species, the identical numbers may not be reproducible with subcultures of the same strain (1) . Therefore, our results showing diverse numerical profiles for serogroups of the E. coli employed support the tenet that biochemical reactions alone have limited value in characterizing a microbial isolate as new or reemergent.
It is known that bacterial agglutination, the classical procedure for serologically identifying E. coli, reveals interrelationships between the various 0 antigen groups that restrict interpretation of specificity (6) . The best way to determine serogroup by this method is to use absorbed antisera. However, because of the number of cross-reacting antigenic factors known and the variability in titers among commercial antisera, as shown recently with Salmonella grouping antisera by Evins et al. (7), absorption studies are time-consuming and costly. In the current study, only CDC antisera were used to identify the 13 serogroups of E. coli reported by Orskov to be associated with urinary tract infections (12) . It is expected that commercial antisera evaluated and found to meet CDC specifications would be satisfactory.
Recent advances in serological technique have provided new approaches to the rapid and specific identification of particulate and soluble antigens. By employing the Cowan I strain of S. aureus, rich in protein A, as a carrier for the Fc portion of IgG in immune serum, one can simplify identification of many bacteria or their antigens (2, 3, 5, 9, 10, 13, 14) . The current report extends this procedure to serogroups of E. coli associated with urinary tract infections. Significantly, except for antiserum 04, all reacted with homologous and not heterologous antigens; antiserum 04 failed to coagglutinate any of the strains representing the 13 serogroups of E. coli. It was reasoned that antiserum 04, which did cause bacterial agglutination, contained IgM and very little, if any, IgG. It is known that the presence and the structure of IgM account for the latter reaction (4), but are ineffectual for coagglutination (11) . Adsorption-elution studies, currently in progress, will determine whether antiserum 04 is deficient in IgG. Kronvall reported that sensitized staphylococcal cells will not only identify specific bacteria, but also will react with such soluble antigens as bovine serum albumin and human chorionic gonadotropin against which the sensitizing antiserum was directed (10) . In the present study, on October 10, 2017 by guest http://jcm.asm.org/ Downloaded from staphylococci coated with CDC antiserum were employed to detect soluble E. coli antigens fixed to the surface of SRBC. Our data indicate that the ensuing pattern of clumping, cohemagglutination, was as rapid, sensitive, and specific as coagglutination. A major disadvantage of cohemagglutination was the time required to extract soluble antigen and to treat SRBC. However, because of the clear visibility of agglutinated SRBC, cohemagglutination conveniently can be adopted as an acceptable alternative method when bacterial or coagglutination reactions are marginal or equivocal.
In conclusion, the employment of Cowan I staphylococci sensitized with CDC antisera may be a practical method for serogrouping by coagglutination the etiological E. coli of a urinary tract infection. The procedure requires minimal technical effort and time. The feasibility of identifying E. coli serogroup more rapidly by adding directly to sensitized staphylococci the sediment of a centrifuged urine specimen, rather than a pure culture of an isolate, currently is being investigated.
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